BioLineRx Ltd.
BLRX
$2.94
-$0.16-5.16%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.99M | 17.05M | 11.66M | 4.80M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.99M | 17.05M | 11.66M | 4.80M | -- |
| Cost of Revenue | 6.87M | 6.04M | 5.15M | 3.69M | -- |
| Gross Profit | 15.13M | 11.00M | 6.51M | 1.11M | -- |
| SG&A Expenses | 32.58M | 35.27M | 34.14M | 31.58M | 26.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.84M | 51.86M | 50.61M | 47.79M | 39.53M |
| Operating Income | -27.85M | -34.82M | -38.96M | -42.99M | -39.53M |
| Income Before Tax | -19.92M | -30.12M | -49.15M | -60.61M | -52.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.92 | -30.12 | -49.15 | -60.61 | -52.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.92M | -30.12M | -49.15M | -60.61M | -52.46M |
| EBIT | -27.85M | -34.82M | -38.96M | -42.99M | -39.53M |
| EBITDA | -25.49M | -33.08M | -37.50M | -42.17M | -38.66M |
| EPS Basic | -0.02 | -0.03 | -0.05 | -0.06 | -0.06 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.03 | -0.04 | -0.04 |
| EPS Diluted | -0.02 | -0.03 | -0.05 | -0.06 | -0.06 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.03 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 4.56B | 4.29B | 4.02B | 3.85B | 3.70B |
| Average Diluted Shares Outstanding | 4.56B | 4.29B | 4.02B | 3.85B | 3.70B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
